UNSPSC 51311601: Nedocromil

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H17NO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0B535E0BN0, chemically known as 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4h-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid but generally known as nedocromil, which bears US NIH Compound Identifier 50294. European Medicines Agency schedules Nedocromil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09179MIG.

UNSPSC 51311601 Nedocromil, a Commodity code, nominally refers to a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code shows little alignment with the category name itself. The three most recent opportunities posted under this code involve naloxone procurement, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceuticals through cooperative purchasing — none of which centers on nedocromil. State and local buyers using this code appear to be soliciting pharmaceutical products and pharmacy services more broadly, including emergency medications, generic drug distribution networks, and pharmacy benefit innovation, rather than nedocromil specifically. The issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (MMCAP administered by Minnesota Department of Administration). Cooperative purchasing vehicles dominate the recent activity, with MMCAP serving participating state and local government facilities across multiple states.

Activity under this code concentrates in Florida, Texas, and Minnesota based on the three most recent opportunities. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, soliciting vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP posted RFP S1070000015802 on January 20, 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products for distribution through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with proposals due March 26, 2026, and contract effectiveness targeted for July 1, 2026. The mismatch between the code name and actual procurement scope suggests this code may be miscoded in state and local systems or used as a catch-all for pharmaceutical procurement where more specific codes do not apply.